Information updates

CFAR Hot Publications

The Centre for Food & Allergy Research (CFAR) Hot Publications session is being held on Wednesday 31 August 2022, 11.30-13.00 AEST, as part of the ASCIA 2022 Conference in Melbourne.  This session features brief oral presentations summarising food allergy research that has recently been published or accepted for publication in peer-reviewed journals. Selection will take into account journal impact factor and novelty of the work.

Submissions are invited for recently or soon-to-be published work for a CFAR Hot Publications presentation by emailing This email address is being protected from spambots. You need JavaScript enabled to view it. by 11 July 2022 with the following information:

Presenter’s name:

Presenter’s primary affiliation:

Presentation title:


Manuscript status* (select one): submitted, under review, accepted, in press, published

Citation information* (as applicable – journal, date submitted/accepted):

Please confirm that you have completed your early bird registration to attend Wednesday 31/8 of the ASCIA 2022 Conference**

*Manuscript status and citation information will be confirmed/updated for selected speakers in late July.

**Applicants should arrange their own day only (Wednesday 31 August) or full conference registration, and CFAR will reimburse Hot Publications speakers for the cost of early bird registration for one day in person ($280-380) or virtual ($220-250) attendance.

Presentations and Q&A will be live on Wednesday 31 August, so speakers must be available to attend the ASCIA 2022 Conference on Wednesday 31 August, either in person or virtually. Speakers who attend virtually will also need to pre-record their presentation.

Continue reading

World Allergy Week 2022

The theme for World Allergy Week 2022 (5 to 11 June) is respiratory allergic diseases, including asthma. The importance of the connection between allergic airway diseases and asthma is reflected in the ASCIA 2022 Conference program and ASCIA online resources:  

  • The ASCIA 2022 Conference program features a Challenging Asthma Symposium as well as a Pollen Allergy Symposium. To view the program book, register and submit an abstract go to Discounted earlybird registration and abstract submission close on 4 July 2022.
  • ASCIA allergic rhinitis e-training for health professionals has recently been updated to include information about chronic rhinosinusitis with nasal polyps (CRSwNP) and is available at
  • ASCIA has recently developed a CRSwNP Position Paper which is available at
  • The ASCIA website includes respiratory allergy resources 

World Allergy Week is a global campaign of the World Allergy Organisation (WAO), which aims to raise awareness of the impact of allergic diseases in our communities. 

WAO will host its official World Allergy Week 2022 webinar on Thursday 9 June, beginning at 8:00 am US Eastern Daylight Time. (Click here to search for your corresponding time zone.) Duration: approximately 90 minutes - Click here to register

The connection between asthma and allergic airway diseases is important, and it is known that asthma and allergies in the upper airways frequently co-exist. This can aggravate breathing difficulty, wheezing, cough, and other respiratory problems. Treating asthma and upper airway allergies together helps improve both problems. Integrated diagnostic and therapeutic approaches become even more important with severe and difficult-to-control disease. Fortunately, there are treatment options and patient education tools that can help to address such challenges.

Continue reading

Autoinflammatory Disease Symposium

The 2nd Australian Autoinflammatory Disease Symposium is being hosted by the Walter and Eliza Hall Institute (WEHI) on Monday 29 August 2022, prior to the ASCIA 2022 Conference in Melbourne.

This symposium will facilitate discussion of autoinflammatory diseases, spanning research, clinical management and a session for patients and their support networks.

This hybrid event can be attended in-person or viewed online and a registration fee of $50.00 applies for in-person attendees and includes morning tea, lunch, afternoon tea and post event refreshments. Registration is free for students and virtual attendees.

Registrations close 5pm (AEST) Monday 8 August 2022 for in person and online attendees. 

To register go to

If you are feeling unwell on the day, please do not attend this event in person, instead view online. WEHI recommends wearing a mask while visiting the institute where social distancing is not possible.

Further details are shown below. 

For event enquiries, please email This email address is being protected from spambots. You need JavaScript enabled to view it.


Science session: The molecular basis of autoinflammation

9:00am -10.30am

  • Kate Schroder (UQ, Science overview, NLRP3 inhibitor update)
  • Najoua Laloui (PeterMac, AID due to cleavage resistant RIPK1)
  • Ivona Aksentijevich (NIH, Ubiquitination and Autoinflammation)
  • Marcia Munoz (Garvan, Prenylation in Mevalonate Kinase Deficiency)

11:00am - 12.30pm

  • Shane Grey (Garvan, Haploinsufficiency of A20)
  • Sophia Davidson (WEHI, Dominant negative Otulin deficiency)
  • Elisabeth Mulazzani (WEHI, Blockade of G-CSF for APLAID)
  • 2 x short talks from abstracts

Clinical session: Treatment and therapy of AID

1.30pm - 3:00pm

  • Ed Giles (Monash, Advances in diagnosis and therapy of EOIBD)
  • Rohit Saldanha (SCH, JAK inhibition for interferonopathies)
  • Samar Ojaimi (Monash) and Thomas Reygaerts (WEHI, CDC42 AID)

3.30pm - 5:00pm

  • Peter McNaughton (QCH, diagnosis of AID)
  • Jonathan Akikusa (RCH, targeting biological therapy for AID)
  • Marco Gattorno (Italy, AID diagnosis and therapy overview)
  • Karen Raymond (Adelaide, Personal take on life with, and research of, AID)

Patient Session: Panel Discussion

5:00pm - 6:00pm

  • Nicole Millis (RareVoices Australia)
  • Marco Gattorno (Italy, Pediatric Rheumatology)
  • Melanie Wong (Westmead, Pediatric Immunology)
  • Jeff Chaitow (SCH, Pediatric Rheumatology)
  • Charlotte Slade (Melb Health, Clinical Immunology)
  • Michael O’Sullivan (FSH, Clinical Immunology)
Abstract Submission

Two talks will be selected from abstracts. Please submit a single page word doc or pdf to be included in the symposium handbook. Include a photo (headshot) of the presenter so that delegates can engage with questions during breaks

Email: This email address is being protected from spambots. You need JavaScript enabled to view it.

Submission deadline is 29 July 2022.

Organising committee
  • Seth Masters (WEHI)
  • Mike Rogers (Garvan)
  • Samar Ojami (Monash)
  • Sam Mehr (RCH)
  • Marcia Munoz (Garvan)

Continue reading

Influenza vaccination and allergy

People with egg allergy may be safely vaccinated with the influenza (flu) vaccine

Information about Influenza vaccination and egg allergy is available on the ASCIA website 

People with mammalian meat allergy may also be safely vaccinated with the influenza (flu) vaccine.

For people with alpha gal sensitisation or mammalian meat allergy or a history of tick anaphylaxis, VAXIGRIP TETRA and AFLURIA QUAD appear to be the safest options, or FLUAD QUAD for people over 65 years, as they do not appear to contain any mammalian products.. 

FLUCELVAX is made in canine kidney and therefore is likely contra-indicated in people with alpha gal sensitisation or mammalian meat allergy.

Continue reading

Support for people with primary immunodeficiencies

The ASCIA Immunodeficiency Strategy for Australia and New Zealand aims to enhance the important work of organisations that support  people with primary immunodeficiencies and their carers, and enable key issues to be addressed, including early diagnosis and improved access to appropriate treatments.

ASCIA commends the outstanding work in advocacy and patient support provided by the following organisations:

IDFA (Immune Deficiencies Foundation Australia) 

pdfIDFA 2022214.33 KB

IDFNZ (Immune Deficiencies Foundation New Zealand)

pdfIDFNZ Update 2022223.12 KB

pdfIDFNZ printed information order form123.96 KB

AusPIPS (Australian Primary Immunodeficiency Patient Support) 

pdfAusPIPS Update 202279.85 KB

HAE (Hereditary Angioedema) Australasia 

pdfHAE Australasia 20221.58 MB

Continue reading

Jorveza® is PBS listed for treatment of EoE

Jorveza® (budesonide) is an orally disintegrating tablet for the treatment of eosinophilic oesophagitis (EoE) in adults, that was listed on the Pharmaceutical Benefits Scheme (PBS) on 1 May 2022.

Jorveza represents the first TGA approved and PBS subsidised medication for adults with this chronic and progressive, immune-mediated, oesophageal disease. The efficacy of Jorveza is supported by data from a phase III, randomised, double-blind, placebo-controlled, parallel group trial. The primary endpoint – clinicohistologic remission after six weeks – was met in 57.6% of patients receiving Jorveza (1mg twice daily; BID) versus 0% in the placebo group (p < 0.0001). At week 6 histologic remission was achieved in 93% of patients administered Jorveza, versus 0% in the placebo group (p < 0.0001). After 12 weeks, clinicohistologic remission was achieved in 84.7% of patients administered Jorveza. Jorveza was well-tolerated, and the most common adverse event reported was mild to moderate local candidiasis. No clinically relevant reduction in morning cortisol levels was documented.

Long-term maintenance treatment is recommended, as patients who discontinue treatment may experience a rapid relapse once remission is achieved. Jorveza is available in 1.0 mg tablets for inducing remission and 0.5/1.0 mg tablets for maintaining remission.

Copies of the product information for Jorveza® can be requested by calling Dr Falk Pharma Australia Pty Ltd on 1800 DRFALK (1800 373 255). 

Information about EoE is available on the ASCIA website

Continue reading

HAE Day - Monday 16 May 2022

Hereditary Angioedema, commonly known as HAE, has been classified as a complement deficiency, which is a type of primary immunodeficiency, and occurs in around one in 50,000 people.  People with HAE have unpredictable, recurrent and rapid swellings, which may involve the skin, gut and airway. HAE attacks interfere with daily life and can be life threatening.

HAE Day 2022 aims to increase awareness of HAE in health professionals and the community. A media release for HAE Day 2022 is available here. 

pdfHAE Day 2022 Media Release210.21 KB

The patient organisation for HAE in Australia and New Zealand is HAE Australasia, and we commend them on their outstanding work in advocacy and patient support.

Our intention is that the ASCIA Immunodeficiency Strategy for Australia and New Zealand supports the important work of HAE Australasia and other patient support organisations and enables key issues to be addressed, including early diagnosis of HAE and access to appropriate treatments.

The ASCIA Immunodeficiency Strategy addresses the need for:

  • Improved education for health professionals to recognise early warning signs of HAE and other primary immunodeficiencies;
  • Improved access to paediatric and adult clinical immunology/allergy specialists;
  • Equitable access to funded treatments in rural, remote and regional centres, as well as urban areas.

The ASCIA Immunodeficiency Strategy for Australia and New Zealand was launched on 29 April 2022. This launch has resulted in substantial media coverage, particularly regarding newborn screening for Severe Combined Immune Deficiency, commonly known as SCID. The purpose of the Strategy is to improve the health and wellbeing of people living with primary immunodeficiencies, (also known as inborn errors of immunity), and minimise the burden on individuals, carers, health services and the community.

The Strategy is focused on primary immunodeficiencies, a diverse group of more than 400 potentially serious, chronic illnesses due to inherited absence or dysregulation of parts of the immune system, that can lead to reduced quality of life and life expectancy.

Information about HAE is available on the ASCIA website:

Continue reading

Paxlovid® is PBS listed for treatment of COVID-19

Paxlovid® (nirmatrelvir/ritonavir tablets) is listed on the Pharmaceutical Benefits Scheme (PBS) from 1 May 2022, as a treatment for COVID-19. Adults can be prescribed PBS-subsidised Paxlovid® by their doctor or nurse practitioner if they have mild to moderate COVID-19 confirmed by a PCR or medically verified RAT, can start treatment within five days of symptom onset, and:  

  • they are 65 years of age or older, with two other risk factors for severe disease (as increasing age is a risk factor, patients who are 75 years of age of older only need to have one other risk factor); or they identify as Aboriginal or Torres Strait Islander origin, and are 50 years of age or older with two other risk factors for severe disease, or
  • they are moderately to severely immunocompromised.

Paxlovid® is not recommended for use in pregnant or breastfeeding women and in women of childbearing potential who are not using contraception. TGA product information on Paxlovid® is available here.

To prioritise Paxlovid® for patients at highest risk of developing severe COVID-19, prescribers should only prescribe Paxlovid®  in accordance with the PBS eligibility criteria, and are strongly discouraged from providing it via private prescription.

For more information read the PBS factsheet here.

Continue reading

More Articles ...

Mod ASCIA Member
Donate to AIFA
go to NAS website
ASCIA Member Login
ASCIA Update

Information for the community about allergic diseases, immunodeficiencies and other immune diseases.
See latest edition here...
Join our mailing list:


ASCIA is the peak professional body of clinical immunology and allergy in Australia and New Zealand
ASCIA promotes and advances the study and knowledge of allergy and other immune diseases

Quick Links


ASCIA is a registered trademark of the Australasian Society of Clinical Immunology and Allergy. All content is subject to copyright for the Australasian Society of Clinical Immunology and Allergy. Read more...

The content for the website is developed and approved by ASCIA Committee and ASCIA Working Party Members. Read more...

Disclaimer I Privacy

The ASCIA website is intended for use by ASCIA members, health professionals and the general public. The content provided is for education, communication and information purposes only and is not intended to replace or constitute medical advice or treatments. Read more...

ASCIA respects your privacy. Read our privacy policy here...

Sponsors | Advertising

ASCIA does not endorse products from sponsoring organisations, nor is it influenced by sponsoring organisations with regard to the content of education programs and websites. 

The ASCIA website does not accept advertising. Any link to a third-party website does not imply any endorsement by ASCIA.



This website is certified by Health On the Net Foundation. Click to verify. This site complies with the HONcode standard for trustworthy health information: verify here.